Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

BACKGROUND: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer. METHODS: In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had advanced p...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Tony S. Mok, Yi Long Wu, Sumitra Thongprasert, Chih Hsin Yang, Da Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Jin Ji Yang, Busyamas Chewaskulyong, Haiyi Jiang, Emma L. Duffield, Claire L. Watkins, Alison A. Armour, Masahiro Fukuoka
التنسيق:	دورية
منشور في:	2018
الموضوعات:	Medicine
الوصول للمادة أونلاين:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=69949162760&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/49303
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
بواسطة: Tony S. Mok, وآخرون
منشور في: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
بواسطة: Yi Long Wu, وآخرون
منشور في: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
بواسطة: Yi Long Wu, وآخرون
منشور في: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
بواسطة: Wu Y., وآخرون
منشور في: (2017)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
بواسطة: Masahiro Fukuoka, وآخرون
منشور في: (2018)

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)
بواسطة: Sumitra Thongprasert, وآخرون
منشور في: (2018)

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)
بواسطة: Thongprasert S., وآخرون
منشور في: (2014)

Lung cancer working group report
بواسطة: Nagahiro Saijo, وآخرون
منشور في: (2018)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
بواسطة: Fukuoka M., وآخرون
منشور في: (2017)

Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
بواسطة: Sumitra Thongprasert, وآخرون
منشور في: (2018)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
بواسطة: Yi Long Wu, وآخرون
منشور في: (2018)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
بواسطة: Yi Long Wu, وآخرون
منشور في: (2018)

Lung cancer response to gefitinib, then erlotinib, then gefitinib again
بواسطة: Wong, A.S., وآخرون
منشور في: (2014)

A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer
بواسطة: Sumitra Thongprasert, وآخرون
منشور في: (2018)

Lung cancer working group report
بواسطة: Saijo N., وآخرون
منشور في: (2017)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
بواسطة: Wu Y.-L., وآخرون
منشور في: (2014)

SYNTHESIS OF QUINAZOLINE DERIVATIVES AS GEFITINIB INTERMEDIATES
بواسطة: Auliya Hafizah, Raysa

Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma
بواسطة: Chalyut Charoentum, وآخرون
منشور في: (2018)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
بواسطة: Chee Khoon Lee, وآخرون
منشور في: (2018)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
بواسطة: Chee Khoon Lee, وآخرون
منشور في: (2018)

Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
بواسطة: Wong, A.S., وآخرون
منشور في: (2014)

Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry
بواسطة: Wang, L.-Z., وآخرون
منشور في: (2014)

Comparison Between Gemcitabine-Carboplatin and Combination of Gemcitabine-Carboplatin and Celecoxib in Urothelial Carcinoma Cell Apoptosis
بواسطة: Widya Sakti Pratama, وآخرون
منشور في: (2019)

Phase II study of 24-hour infusion of paclitaxel (Intaxel) with carboplatin in advanced non-small cell lung cancer.
بواسطة: Chaiyut Charoentum, وآخرون
منشور في: (2018)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
بواسطة: Lee C., وآخرون
منشور في: (2017)

EFFICACY OF GEFITINIB AND ERLOTINIB IN NON-SMALL-CELL LUNG CARCINOMA
بواسطة: Afrita Amalia Laitupa, -, وآخرون
منشور في: (2019)

SYNTHESIS OF VARIOUS GEFITINIB INTERMEDIATE DERIVATIVE AS ANTI-CANCER DRUGS
بواسطة: Lutfi Sa'adah, Pipih

Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
بواسطة: Thongprasert S., وآخرون
منشور في: (2014)

Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
بواسطة: Thongprasert S., وآخرون
منشور في: (2014)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
بواسطة: Sudo, M., وآخرون
منشور في: (2014)

Two-year outcome of concurrent chemoradiation with carboplatin with or without adjuvant carboplatin/fluorouracil in nasopharyngeal cancer: A multicenter randomized trial
بواسطة: Imjai Chitapanarux, وآخرون
منشور في: (2020)

Short-hairpin RNA library: Identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer
بواسطة: Sudo M., وآخرون
منشور في: (2020)

The Differences of Apoptosis Effects Between Combination of Meloxicam with Gemcitabine-Carboplatin Chemotherapy Compared to Gemcitabine-Carboplatin Chemotherapy Alone in Urothelial Carcinoma Culture Cells
بواسطة: Ananta Cahyo Nugroho, وآخرون
منشور في: (2019)

Dietary counseling outcomes in locally advanced unresectable or metastatic cancer patients undergoing chemotherapy
بواسطة: Napawan Sukaraphat, وآخرون
منشور في: (2018)

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
بواسطة: James Chih Hsin Yang, وآخرون
منشور في: (2018)

PERBEDAAN EFEK APOPTOSIS PEMBERIAN KOMBINASI MELOKSIKAM DAN KEMOTERAPI GEMCITABINE CARBOPLATIN DIBANDINGKAN KEMOTERAPI GEMCITABINE CARBOPLATIN PADA SEL KULTUR KARSINOMA UROTHELIAL
بواسطة: Ananta Cahyo Nugroho, NIM01131896305
منشور في: (2018)

First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results from a Randomized Phase III Trial
بواسطة: Mark Boye, وآخرون
منشور في: (2018)

Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer
بواسطة: Kietpeerakool C., وآخرون
منشور في: (2014)

Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer
بواسطة: Chumnan Kietpeerakool, وآخرون
منشور في: (2018)

Ring-Opened Adducts of the Anticancer Drug Carboplatin with Sulfur Amino Acids
بواسطة: Barnham, K.J., وآخرون
منشور في: (2014)